Adolor — Technical Presentation (September 2003)
21 slides from Adolor's technical presentation, Sep 23, 2003
Slide 1: Results from Alvimopan Phase 3 Clinical Study 14CL313
Results from Alvimopan Phase Clinical Study 14CL313 September 23, 2003
Slide 2: Forward-Looking Statements
Forward-Looking Statements This oral presentation and the questions and answers that follow contain forward- looking statements including but not limited to the following: Our forward-looking statements are subject to risks and uncertainties, known and unknown, that could cause actual results and de
Slide 3: Overview: Alvimopan for the Management of Postoperative Ileus, Study 14CL313
Alvimopan demonstrated a statistically significant difference in the primary endpoint, Time to Recovery of GI Function, in both treatment groups A difference of 13 and 20 hours for alvimopan 6 and 12 mg, respectively, was seen in the Time to Hospital Discharge Order Written Alvimopan was generally w
Slide 4: Study design: double-blind, placebo-controlled, randomized, multi-center
Double-blind, placebo-controlled, randomized, multi-center 510 patients enrolled across 3 treatment groups (alvimopan 6 or 12 mg, or placebo) Patients were to receive their first dose at least two hours prior to surgery, and then twice a day until Hospital Discharge or up to 7 days post-surgery Post
Slide 5: Inclusion Criteria
Inclusion Criteria Male or Female 18 years or older Small or Large Bowel Resection or Radical Abdominal Hysterectomy Subject is scheduled for postoperative pain management with intravenous Patient Controlled Analgesia with opioids Nasogastric tube to be removed at the end of surgery or by Postoperat
Slide 6: Primary and Secondary Efficacy Endpoints
Secondary Efficacy Endpoints Proportion of Responders Time to be Ready for Discharge based solely on Recovery of Gastrointestinal Function Time to First Flatus Time to First Bowel Movement Time to First Solid Food Time to Hospital Discharge Order Written Time to Tolerating Solid Food and First Bowel
Slide 7: Subjects Enrolled
Subjects Enrolled (N = 510) Modified Intent-to-Treat (N = 469) Placebo (N = 149) Alvimopan 6 mg (N = 155) Alvimopan 12 mg (N = 165) Completed - 115 D/C = 34 AE = 26 Other = 8 Completed - 129 D/C = 26 AE = 18 Other = 8 Completed - 141 D/C = 24 AE = 14 Other = 10 Postoperative Ileus -- Study 14CL313
Slide 8: Demographics
50.1% 53.3% 43.9% 53.0% Female (%) 87.9% 60.9 Placebo (N=149) 86.5% 59.3 6 mg (N=155) 87.9% 61.3 12 mg (N=165) 87.4% Caucasian (%) 60.5 Mean Age Overall (N=469) Overall Demographics Alvimopan for the Management of Postoperative Ileus -- Study 14CL313
Slide 9: Time to Recovery of GI Function: 6 mg vs. placebo
6 mg vs. placebo: hazard ratio = 1.28, P<0.05 (Cox Proportional Hazard Model) 6 mg Placebo Mean difference = 14.6 hours (Kaplan Meier Estimates) Time to Recovery of GI Function Postoperative Ileus -- Study 14CL313
Slide 10: Time to Recovery of GI Function: 12 mg vs. placebo
12 mg vs. placebo: hazard ratio = 1.54, P<0.01 (Cox Proportional Hazard Model) Placebo 12 mg Mean difference = 22.0 hours (Kaplan Meier Estimates) Time to Recovery of GI Function Postoperative Ileus -- Study 14CL313
Slide 11: Time to Hospital Discharge Order Written
Time to Hospital Discharge Order Written 6 mg dose vs. placebo Hazard ratio = 1.25 Approximately 13 hours earlier average time to hospital discharge order written 12 mg dose vs. placebo Hazard ratio = 1.42* Approximately 20 hours earlier average time to hospital discharge order written *Statisticall
Slide 12: Hospital Discharge Order Written by Postoperative Day
Hospital Discharge Order Written by Postoperative Day % of Subjects 3.7 Est. Avg. Days 4.2 Postoperative Ileus -- Study 14CL313 Additional Analysis:
Slide 13: Hospital Discharge Order Written by Postoperative Day: Additional Analysis
% of Subjects 3.3 Est. Avg. Days 4.2 Postoperative Ileus -- Study 14CL313 Hospital Discharge Order Written by Postoperative Day Additional Analysis:
Slide 14: Time to Tolerating Solid Food and First Bowel Movement
Time to Tolerating Solid Food and Time to First Bowel Movement (“Solids In, Solids Out”) 6 mg dose vs. placebo Hazard ratio = 1.39* Approximately 20 hours earlier average time to “Solids In, Solids Out” 12 mg dose vs. placebo Hazard ratio = 1.67* Approximately 28 hours earlier average time to “Solid
Slide 15: Proportion of Responders
Proportion of Responders Responders (%) Responders are defined as subjects who achieved GI recovery in < 108 hours Postoperative Ileus -- Study 14CL313
Slide 16: Alvimopan was generally well tolerated
Alvimopan was generally well tolerated Most frequent adverse events were : Placebo 6 mg 12 mg (N = 165) (N = 169) (N = 176) Nausea 64.2% 60.9% 54.5% Vomiting 25.5% 24.3% 19.9% Hypotension 13.9% 13.6% 13.6% Safety Population Discontinuations for adverse events: Postoperative Ileus -- Study 14CL313 MI
Slide 17: Time to Recovery of GI Function Compared with Placebo
< 0.01 0.11 < 0.05 < 0.01 P-value 1.54 1.23 1.28 1.44 Hazard ratio 14CL313 14CL302 14CL313 14CL302 Study Alvimopan 12 mg Alvimopan 6 mg Time to Recovery of GI Function Alvimopan for the Management of Postoperative Ileus Compared with Placebo
Slide 18: Top 3 Adverse Events by Study
15.0% 32.0% 67.3% 14CL302 (N=153) 13.9% 25.5% 64.2% 14CL313 (N=165) 13.6% 11.6% 13.6% 12.0% Hypotension 19.9% 15.1% 24.3% 25.3% Vomiting 54.5% 56.8% 60.9% 64.0% Nausea 14CL313 (N=176) 14CL302 (N=146) 14CL313 (N=169) 14CL302 (N=150) Study Top 3 AE’s 12 mg 6 mg Placebo Postoperative Ileus
Slide 19: Summary
Alvimopan demonstrated a statistically significant difference in the primary endpoint in both treatment groups A difference of 15 and 22 hours for alvimopan 6 and 12 mg, respectively, was seen in the Time to recovery of GI Function A difference of 13 and 20 hours for alvimopan 6 and 12 mg, respectiv
Slide 20: Postoperative Ileus study timeline and NDA submission target
Results announced today Announce Results 1Q 2004 Announce Results 4Q 2003 Results announced in April 2003 Target 660* N Study * denotes target number NDA submission will depend on achieving confirmatory clinical trial results; and timing of any submission is dependent on timing of accrual completion
Slide 21: Adolor Corporation
adolor CORPORATION d@or